Kerstein David 4
4 · Theseus Pharmaceuticals, Inc. · Filed Feb 23, 2022
Insider Transaction Report
Form 4
Kerstein David
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2022-02-18+150,000→ 150,000 totalExercise: $11.21Exp: 2032-02-17→ Common Stock (150,000 underlying)
Footnotes (1)
- [F1]The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 18, 2023 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.